This website uses cookies to enhance the user experience.
21st logo
||
C

CHIRON PHARMASYNTH AS983 903 827

Process industry
Limited company
Arkitekt Ebbells veg 26 7041 TRONDHEIM, Norge

CHIRON PHARMASYNTH AS

Operating
Drive utvikling, produksjon og salg av kjemiske produkter, formidling og salg av kompetanse og alt som dermed står i forbindelse, samt delta i annen økonomisk virksomhet av interesse.
Utvikling, produksjon og salg av kjemiske produkter.

Keywords

productionmedicinal substancesdrugsantibioticsbasic vitaminssalicylic acido-acetylsalicylic acidprocessing of blood

Links

Organization

CEO
MS

Marianne Sinnes1969

Chairman of the board
PR

Philip Rinaldi1963

Years since formation
25 years
since Nov 17, 2001
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
100,000
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Total operating income 2025
24,412,120
NOK
Annual total result 2025
648,632
NOK
Total equity 2025
19,508,540
NOK
Last update: Aug 6, 2026

Management

Management / administration

NameRoleShares
MS

Marianne Sinnes

1969

Managing Director/CEO-

Board

NameRoleShares
PR

Philip Rinaldi

1963

Chairman-
MS

Marianne Sinnes

1969

Board Member-

Others

NameRoleShares
E
ERNST & YOUNG AS
Auditor-
A
ADMENTO AS
Accountant-
Last update: Jul 7, 2026

Ownership

Company shareholders

NameShare classTotal number of sharesShare
C
CHIRON AS
Ordinary shares
100,000
100 %
Last update: Jun 2, 2025

Group structure

Financials

in NOK

Summary

Year20252024202320222021
Total operating income
24,412,120
26,101,561
23,983,984
15,919,267
10,926,390
Annual Total Result
648,632
-257,881
4,290,755
1,805,539
3,292,183
Total assets
32,548,948
31,964,352
32,931,220
28,458,061
25,541,100
Total liabilities
13,040,408
13,104,444
13,813,430
10,880,072
9,768,649
Total equity
19,508,540
18,859,908
19,117,790
17,577,989
15,772,451

P&L

Year20252024202320222021
Total operating income
24,412,120
26,101,561
23,983,984
15,919,267
10,926,390
Total operating costs
23,783,776
26,824,043
19,021,274
14,272,185
7,090,802
Operating result
628,344
-722,482
4,962,710
1,647,081
3,835,589
Financial income/costs
20,288
464,600
103,956
245,644
8,978
Profit before tax
648,632
-257,881
5,066,666
1,892,726
3,844,567
Total tax & extraordinary income/cost
0
0
775,911
87,187
552,384
Annual Total Result
648,632
-257,881
4,290,755
1,805,539
3,292,183

Balance overview

Year20252024202320222021
Total fixed assets
0
0
0
0
0
Total current assets
32,548,948
31,964,352
32,931,220
28,458,061
25,541,100
Total assets
32,548,948
31,964,352
32,931,220
28,458,061
25,541,100
Short term debt
13,040,408
13,104,444
13,813,430
10,880,072
9,768,649
Long term debt
0
0
0
0
0
Total liabilities
13,040,408
13,104,444
13,813,430
10,880,072
9,768,649
Contributed capital
1,775,000
1,775,000
1,775,000
1,775,000
1,775,000
Retained earnings
17,733,540
17,084,908
17,342,790
15,802,989
13,997,451
Total equity
19,508,540
18,859,908
19,117,790
17,577,989
15,772,451
Total equity and liabilities
32,548,948
31,964,352
32,931,220
28,458,061
25,541,100

Classification

21st company classification
BETA
Small company
Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1
Main industrial group
Manufacture of basic pharmaceutical products
21.10
Industrial group
Manufacture of basic pharmaceutical products
21.100
Industrial group
Manufacture of basic pharmaceutical products